CANTEL MEDICAL CORP. (NYSE:CMD) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07 Submission of Matters to a Vote of Security Holders.
At the 2017 Annual Meeting, held on January 3, 2018, five proposals were voted on by the Company’s stockholders.The proposals are described in detail in the Company’s definitive proxy statement filed on November 28, 2017 (the “Proxy Statement”) in connection with the 2017 Annual Meeting and summarized below.
A final voting report was produced by Broadridge Financial Solutions,Inc., the independent inspector of election for the 2017 Annual Meeting, certifying the following results on the five proposals:
Proposal 1 The stockholders elected all ten director nominees to serve as members of the Company’s board of directors until the Company’s 2018 Annual Meeting of Stockholders.
Name |
For |
Withheld |
Abstain |
Broker Non-Votes |
Alan R. Batkin |
36,775,973 |
744,667 |
7,468 |
2,244,375 |
Ann E. Berman |
37,321,222 |
199,726 |
7,160 |
2,244,375 |
Charles M. Diker |
36,841,392 |
671,682 |
15,034 |
2,244,375 |
Mark N. Diker |
37,026,153 |
493,746 |
8,209 |
2,244,375 |
Anthony B. Evnin |
37,151,885 |
261,417 |
114,806 |
2,244,375 |
Laura L. Forese |
37,312,092 |
209,227 |
6,789 |
2,244,375 |
George L. Fotiades |
37,304,318 |
216,105 |
7,685 |
2,244,375 |
Jorgen B. Hansen |
37,021,850 |
490,810 |
15,448 |
2,244,375 |
Ronnie Myers |
37,208,250 |
209,946 |
109,912 |
2,244,375 |
Peter J. Pronovost |
37,284,247 |
192,420 |
51,441 |
2,244,375 |
Proposal 2 The stockholders approved, on an advisory basis, the compensation of the Company's Named Executive Officers.
For |
Against |
Abstain |
Broker Non-Votes |
36,679,402 |
832,016 |
16,690 |
2,244,375 |
Proposal 3 The stockholders approved, on an advisory basis, the frequency of future advisory votes on the compensation of the Company’s Named Executive Officers.
One Year |
Two Years |
Three Years |
Abstain |
Broker Non-Votes |
31,846,902 |
32,001 |
5,630,874 |
18,331 |
2,244,375 |
Proposal 4 The stockholders approved the amendment of the Company's By-Laws to designate the Delaware Court of Chancery as the exclusive forum for certain legal actions.
For |
Against |
Abstain |
Broker Non-Votes |
22,510,534 |
15,002,903 |
14,671 |
2,244,375 |
Proposal 5The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s Independent Registered Public Accounting Firm for the fiscal year ending July31, 2018.
For |
Against |
Abstain |
39,496,965 |
268,737 |
6,781 |
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
CANTEL MEDICAL CORP ExhibitEX-3.1 2 exhibit-cantelbyxlaws.htm EXHIBIT 3.1 Exhibit Exhibit 3.1 CANTEL MEDICAL CORP. BY-LAWS(As amended through January 3,…To view the full exhibit click here
About CANTEL MEDICAL CORP. (NYSE:CMD)
Cantel Medical Corp. is a provider of infection prevention products and services in the healthcare market. The Company’s operating segments include Endoscopy; Water Purification and Filtration; Healthcare Disposables, and Dialysis. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies. The Company’s Water Purification and Filtration segment includes water purification equipment and services, filtration and separation products, and disinfectant, sterilization and decontamination products and services. Its Healthcare Disposables segment includes single-use, infection prevention and control healthcare products. The Company’s Dialysis segment includes medical device reprocessing systems, sterilants/disinfectants, dialysate concentrates and other supplies for renal dialysis. The Company offers a range of filters utilizing hollow fiber membrane technology.